Since the first anti-PCSK9 antibody Evolocumab was approved in 2015, prospective long-time studies investigating the effect of PCSK9 inhibition on cerebral Aβ burden and cognitive functions will show if these antibodies effectively enhance Aβ brain clearance in humans and could be a potential treatment for AD. This evidence concerns the gene PCSK9 and Alzheimer disease.